Jacque Noel, MD
Gastroenterology · Lafayette, LANPI 1558371450
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $9,204 of the $11,873 with a category attached, or 77.5%. 30 manufacturers reported payments, led by AbbVie at 27.6% of the total.
Across 546 payments — averaging $21.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Olympus Corporation$2K
- Takeda Pharmaceuticals U.S.A., Inc.$1K
- Johnson & Johnson$1K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$550
- QOL Medical, LLC$399
- plus $3K from 24 others
Across 13 payments — averaging $5872.77 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$36K
- Bausch Health US, LLC$27K
- Phathom Pharmaceuticals, Inc.$13K
What the payments were for
- Consulting fees$1,99517%
- Speaking & faculty fees$2002%
- Food & beverage$9,20478%
- Education$4744%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 199 | $3,275 |
| Olympus Corporation | 5 | $1,995 |
| Takeda Pharmaceuticals U.S.A., Inc. | 89 | $1,330 |
| Johnson & Johnson(2 entities) | 57 | $1,251 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 35 | $550 |
| QOL Medical, LLC | 21 | $399 |
| Intercept Pharmaceuticals, Inc. | 18 | $348 |
| Ardelyx, Inc. | 20 | $321 |
| Phathom Pharmaceuticals, Inc. | 20 | $210 |
| Pfizer | 14 | $205 |
| Shire North American Group Inc | 1 | $200 |
| Sanofi | 3 | $187 |
| Fresenius Kabi USA, LLC | 2 | $180 |
| Gilead | 8 | $178 |
| Ipsen Biopharmaceuticals, Inc | 8 | $173 |
| Medtronic | 4 | $162 |
| Janssen Scientific Affairs, LLC | 1 | $124 |
| UCB, Inc. | 1 | $124 |
| Lilly USA, LLC | 6 | $105 |
| Bristol Myers Squibb | 5 | $99 |
| Merck | 6 | $92 |
| Ironwood Pharmaceuticals, Inc | 6 | $76 |
| Celltrion USA Inc. | 4 | $73 |
| Evoke Pharma, Inc. | 3 | $59 |
| Braintree Laboratories, Inc. | 4 | $56 |
| Aimmune Therapeutics, Inc. | 2 | $36 |
| Ferring Pharmaceuticals Inc. | 1 | $19 |
| Amgen | 1 | $17 |
| Biocon Biologics Inc | 1 | $15 |
| Boehringer Ingelheim | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,873 in reported general payments places this provider in the 80th percentile of 254 gastroenterology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 19 | $537,281 |
| Skyrizi On-BodyRisankizumab-Rzaa | 14 | $294,266 |
| Humira(Cf) PenAdalimumab | 28 | $222,887 |
| Yuflyma(Cf) Autoinject (2 Pck)Adalimumab-Aaty | 11 | $84,133 |
| LinzessLinaclotide | 68 | $37,586 |
| ViberziEluxadoline | 16 | $25,441 |
| ClenpiqSod Picosulf/Mag Ox/Citric Ac | 80 | $13,623 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 201 | $12,917 |
| Mesalamine | 29 | $7,678 |
| Pantoprazole Sodium | 502 | $7,105 |
| Dexlansoprazole DrDexlansoprazole | 29 | $7,070 |
| Esomeprazole Magnesium | 58 | $6,147 |
| ErythromycinErythromycin Base | 15 | $5,788 |
| SutabSod Sulf/Pot Chloride/Mag Sulf | 30 | $4,792 |
| Colestipol Hcl | 84 | $4,011 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $1,251 | $537,28119 claims |
| AbbVieLinzess, Viberzi | $3,275 | $63,02684 claims |
| Ferring Pharmaceuticals Inc.Clenpiq | $19 | $13,62380 claims |
| Braintree Laboratories, Inc.Sutab, Suflave | $56 | $6,59145 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 254 gastroenterology providers in Louisiana.
Other gastroenterology in Lafayette
- Eric TrawickLafayette$54K
- Erick SalvatierraLafayette$27K
- Jacob KarrLafayette$10K
- Jacob BreauxLafayette$9K
- Jonathon ChapmanBaton Rouge$998K
- Conar FittonKenner$955K
- Gia LandryBaton Rouge$511K
- Charles MonierThibodaux$448K
- Nathaniel RanneyCovington$392K
- Georges CatinisMetairie$346K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.